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Abstract 
Background: Chagas disease, caused by the protozoan Trypanosoma cruzi, is a neglected disease that affects ~7 
million people worldwide. Development of new drugs to treat the infection remains a priority since those currently 
available have frequent side effects and limited efficacy at the chronic stage. Natural products provide a pool of diver‑
sity structures to lead the chemical synthesis of novel molecules for this purpose. Herein we analyzed the anti‑T. cruzi 
activity of nine alkaloids derived from plants of the family Amaryllidaceae.
Methods: The activity of each alkaloid was assessed by means of an anti‑T. cruzi phenotypic assay. We further evalu‑
ated the compounds that inhibited parasite growth on two distinct cytotoxicity assays to discard those that were 
toxic to host cells and assure parasite selectivity.
Results: We identified a single compound (hippeastrine) that was selectively active against the parasite yielding 
selectivity indexes of 12.7 and 35.2 against Vero and HepG2 cells, respectively. Moreover, it showed specific activity 
against the amastigote stage  (IC50 = 3.31 μM).
Conclusions: Results reported here suggest that natural products are an interesting source of new compounds for 
the development of drugs against Chagas disease.
Keywords: Chagas disease, Trypanosoma cruzi, Alkaloids, Amaryllidaceae, Hippeastrine, Phenotypic assays, 
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Background
Chagas disease (or American trypanosomiasis) is a 
neglected infectious disease caused by the protozoan 
parasite Trypanosoma cruzi (order Kinetoplastida; 
family Trypanosomatidae). It is estimated that ~7 mil-
lion people are affected by the disease, mainly in Latin 
America where T. cruzi infection is endemic [1].
The disease progresses in two phases. There is first 
a short acute phase that is usually asymptomatic and 
thus goes unnoticed. This is followed by a chronic phase 
characterized by absent or slow progression of clinical 
manifestations [2]. Nonetheless, it is estimated that ~40% 
of those chronically infected will ultimately develop 
disruptive damage to the heart and/or digestive tract 
(esophagus and colon) tissues, which can lead to the for-
mation of mega-syndromes and death if untreated [2, 3].
Since the 1970s only two drugs have been available to 
treat T. cruzi infections: benznidazole (BNZ) and nifur-
timox (NFX) [1]. Both have good efficacy and tolerability 
when administered to infected new-borns [4]. But their 
efficacy diminishes at the chronic stage, which is usually 
diagnosed at adulthood with serological tests that detect 
specific anti-T. cruzi type G immunoglobulins [1]. More-
over, both drugs have long regimens of administration 
that entail the advent of frequent adverse events which 
often drive to treatment discontinuation [5–7]. There 
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is thus an urgent unmet need of safer and more effica-
cious drugs for the treatment of chronic Chagas disease, 
for which natural products may represent a promising 
approach to discover new lead compounds [8–10].
In this regard, members of the family Amaryllidaceae 
have attracted considerable attention in the last few years 
due to their unique alkaloid composition with multiple 
biological activities [11]. Amaryllidaceae plants have been 
studied for their potential application as a source of anti-
cancer, anti-inflammatory, antimicrobial, anti-parasitic 
and anticholinesterase activities [12]. In fact, they have 
been used for centuries as part of traditional treatments 
for fever, swelling, cancer or malaria [12]. Remarkably, in 
2001 the Food and Drug Administration (FDA) approved 
the use of galanthamine (trade name Razadyne), an alka-
loid identified from the Amaryllidaceae plant Galanthus 
woronowi, to treat Alzheimer’s disease [13].
Alkaloid constituents found in these plants are classified 
in eight groups based on structure and biogenesis from the 
common precursor O-methylnorbelladine: galanthamine; 
lycorine; crinine; haemanthamine; homolycorine; narcicla-
sine; tazettine; and montanine [14]. The unique structure 
of this set of alkaloids provides a viable platform for phyto-
chemical‐based drug discovery [8]. With the aim to identify 
prospective drug development starting points that could 
eventually become new therapeutic solutions for Chagas 
disease we have adapted an in vitro anti-T. cruzi phenotypic 
assay based on the parasite Tulahuen strain engineered 
to express a bacterial β-galactosidase gene [15] and green 
monkey epithelial cells (Vero) as hosts. We evaluated the 
anti-T. cruzi activity of nine crystalized alkaloid compounds 
extracted from members of the Amaryllidaceae family: lyco-
rine, hippeastrine, crinine, haemanthamine, narciclasine, 
tazettine, montanine, sanguinine and 1-O-acetylcaranine 
(Fig. 1) [16]. In all the assays performed we always included 
the standard anti-parasitic drug BNZ for comparison.
In order to unveil the specific T. cruzi growth inhibitory 
capacity of those compounds that were found active in the 
anti-parasitic assay, we further used two secondary biologi-
cal assays to determine the compounds’ level of cytotoxic-
ity. These were respectively based on the same host Vero 
cells and in the human hepatocellular carcinoma cell line 
HepG2. Finally, we determined the anti-amastigote specific 
activity of the only compound that was revealed to hold 
selective anti-parasitic activity. Results obtained were par-
ticularly promising for the compound hippeastrine from 
Narcissus cv. Salome [17] and they are discussed herein.
Methods
Collection of purified alkaloid compounds 
from Amaryllidaceae plants
Lycorine, hippeastrine, crinine, haemanthamine, narci-
clasine, tazettine, montanine, sanguinine and 1-O-acetyl-
caranine alkaloids were isolated from extracts of different 
Narcissus species [16, 18]. The information of all the 
compounds studied can be found in the extensive chap-
ter by Bastida et al. [16]. In brief, the procedure followed 
to identify the alkaloids within the corresponding plant 
extract was as follows: plant material (60 mg) was mac-
erated with MeOH; the mix was filtered and the solvent 
evaporated to dryness. After that, extracts were acidi-
fied with 500 µl of  H2SO4 (2%, v/v). The neutral material 
was removed with diethyl ether and basified with 200 
µl  NH4OH (25 %, v/v). Then, 750 µl of diethyl ether was 
added to separate the organic phase, this was repeated 
twice, and the solvent evaporated to dryness. All com-
pounds were crystals, obtained after three successive 
crystallization rounds to ensure maximum purity. They 
were subjected to a combination of chromatographic 
techniques and alkaloids were identified by GC-MS and 
NMR [16, 17] (Additional file 1: Figures S1, S2). In order 
to obtain milligrams of product, the corresponding scale-
up was performed as previously described [19, 20].
Host cells cultures
Vero (green monkey kidney epithelial cells), LLC-MK2 
(Reshus monkey kidney epithelial cells) and HepG2 
(human liver epithelial cells) cultures were maintained 
with DMEM supplemented with 1% penicillin-strep-
tomycin (100 units/ml of penicillin and 100 µg/ml of 
streptomycin; P-S) and 10% heat inactivated fetal bovine 
serum (FBS) at 37  °C, 5%  CO2 and > 95% humidity as 
described by Buckner et al. [15]. HepG2 were also supple-
mented with 1× non-essential amino acids (ref. 01-340-
1B; Biological Industries, Beit-Haemek, Israel).
Culture of T. cruzi parasites
Trypanosoma cruzi parasites from the Tulahuen 
strain (discrete typing unit, DTU VI) expressing 
β-galactosidase were kindly provided by Dr Fred Buck-
ner (University of Washington, Seattle, USA) and 
maintained using LLC-MK2 cells as hosts in DMEM 
supplemented with 2% FBS and 1% P-S as previously 
described [15]. Free-swimming trypomastigotes were 
purified by centrifugation of the cell culture superna-
tant for 7 min at 2500× rpm using a low break speed, 
then allowing them to swim out of the pellet [21]. Puri-
fied trypomastigotes were used to keep the parasite 
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cycle in LLC-MK2 cells and for the performance of the 
anti-parasitic assays. In the last case, an extra round of 
centrifugation was performed to remove phenol red 
from the maintenance DMEM and replace with a phe-
nol red-free DMEM medium, which was supplemented 
with 1% P-S-glutamine, 2% FBS, 1 mM sodium-pyru-
vate and 25 mM HEPES [21].
Assay to detect T. cruzi growth inhibition in 96‑well plates
Our assay is based on Vero cells as hosts and infective 
trypomastigotes from the Tulahuen strain that express 
the bacterial β-galactosidase enzyme as reporter activ-
ity [15]. First, alkaloids were added in the first column 
of a 96-well tissue culture treated plates at an initial 
concentration of 100 µM and diluted in assay medium 
into the next columns of the plate to conform dose-
response plate-maps following either a 1:2 or 1:3 fold 
pattern. Then, Vero cells were detached from their 
growing flasks, counted and diluted at a concentration 
of 1 × 106 cells per ml. Trypan blue staining was used 
to check their viability, which had to be > 95% to pro-
ceed. In conjunction, purified trypomastigotes were 
counted and diluted at a concentration of 1 × 106 cells 
per ml. We directly mixed Vero cells and trypomastig-
otes in a falcon tube in a sufficient volume so as to add 
100 μl of the mix per well (50,000 Vero cells and 50,000 
trypomastigote cells per well; with the multiplicity of 
infection, MOI = 1). The percentage of DMSO in all 
wells was always kept below 0.5%.
The reference drug BNZ was used as a control of drug 
growth inhibition in each run, whereas each plate con-
tained its own negative (maximum parasite growth; 
Vero cells plus parasites without drugs) and positive 
(minimum parasite growth; trypomastigote forms 
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Fig. 1 Chemical structures of the alkaloids evaluated in this study
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galactosidase activity) controls. Note that trypomastig-
otes are unable to multiply in the absence of suscepti-
ble host cells. Plates were incubated for 4 days at 37 °C 
[21], with the readout performed by adding 50 µl per 
well of a PBS solution containing 0.25% NP40 and 500 
µM chlorophenol red-β-d-galactoside (CPRG) sub-
strate, as previously described [21]. Upon addition of 
the substrate, plates were further incubated at 37  °C 
for another 4 h and the absorbance read out at 590 
nm using an Epoch Gene5 spectrophotometer (Biotek, 
Winooski, USA). All experiments were performed at 
least in triplicate.
Anti‑amastigote specific activity of progressed compound 
(hippeastrine)
Using Vero cells as hosts and the recombinant T. cruzi 
strain expressing β-galactosidase, we further adapted 
the anti-parasitic assay described above to determine 
whether the anti-parasitic activity was specific against the 
intracellular amastigote forms. In brief, we plated 50,000 
Vero cells per well in a 96-well plate and allowed them 
to attach for 1.5 h. Then, we infected the monolayers 
with 50,000 purified trypomastigotes per well (MOI = 1) 
that were allowed for 1 h to adsorb and enter the cells 
before being washed with PBS three times. Finally, assay 
medium was added and used to dilute hippeastrine 
and BNZ in a dose-response pattern. In each plate we 
included the same controls as for the anti-T. cruzi assay. 
Test plates were incubated for 96 h and the assay readout 
was performed as described above.
Toxicity assays with Vero and HepG2 cells
For the cell toxicity assays, compounds were added to 
tissue culture treated 96-well plates following a dose-
response dilution pattern, 1:2 or 1:3, with a starting 
concentration of 400 µM or 800 µM per well in the first 
column of the plate. Cell viability was checked upon cell 
counting with Trypan blue and we only proceeded if 
viability was > 95%. Vero cell suspension was diluted at 
a concentration of 5 × 105 cells per ml before adding 100 
µl per well. In the case of HepG2 cells, we used a dilution 
of 3.2 × 104 cells per ml. Each test plate or run contained 
its own negative (untreated cells) and positive (medium 
alone) controls. Plates were incubated at 37 °C for 4 days 
in the case of Vero cells, and 2 days for HepG2 cells. We 
then added 50 µl per well of a PBS solution containing 
10% Alamar Blue reagent (Thermo Fisher Scientific, 
Eugene, USA) and incubated the plates for 6 h at 37  °C 
before reading the fluorescence intensity in a Tecan Infi-
nite M  Nano+ reader (Tecan, Männedorf, Switzerland) 
(excitation: 530 nm, emission: 590 nm). The percentage 
of DMSO in all wells was always kept below 0.5%. All 
experiments were performed at least in triplicate.
Data analysis
Absorbance and fluorescence values derived from the 
anti-T. cruzi and cell toxicity assays were normalized to 
the controls [22].  IC50 and  TC50 values were determined 
using GraphPad Prism 7 software (version 7.00, 2016) 
using a non-linear regression analysis model defined by 
the equation:
These  IC50 and  TC50 values are the compound con-
centrations capable of inhibiting growth of parasites and 
cells by 50%, respectively. Z’-values were calculated as 
described previously [23]. Values provided are the mean 
and standard deviation (SD) of at least three independent 
experiments.
Results and discussion
Quality assessment of the anti‑T. cruzi and cell toxicity 
assays
As part of the process of setting up the biological assays 
we calculated their Z’ parameter to assess reproducibility 
and statistical robustness [23]. In general, assays with a 
Z’ between 0.5 and 1 are considered appropriate for the 
screening of compounds [23]. Remarkably, our anti-par-
asitic assay had a very good performance and its Z’-value 
remained consistently > 0.5 with an average value of 0.89 
(0.097) (Fig.  2a). Regarding the two cytotoxicity assays 
used in this study, we retrieved Z’ = 0.76 (0.067) for the 
assay based on Vero cells, and a Z’ = 0.73 (0.054) for the 
assay based on HepG2 cells (Fig. 2c–e).
Additionally, in every run of the T. cruzi growth inhi-
bition assay and Vero cell toxicity assay performed, we 
included the reference drug BNZ as a control, whereas 
the reference drug digitoxin (DTX) [24] was included in 
all the HepG2 cells toxicity assays. Overall, averaged  IC50 
and  TC50 values for BNZ were 1.56 (0.39) μM and 173.4 
(43.57) μM, respectively (Fig. 2b–d, Additional file 1: Fig-
ure S3), which correlates with previous reports [21, 25]. 
The digitoxin  TC50 mean value in the HepG2 cell assay 
was 0.29 (0.14) μM (Fig. 2f, Additional file 1: Figure S3).
Anti‑T. cruzi activity of the alkaloids extracted 
from Amaryllidaceae
As in other widely used anti-T. cruzi assays [21, 22, 26] we 
relied on the genetically robust T. cruzi Tulahuen strain 
expressing beta-galactosidase activity as a surrogate of 
parasite growth [15]. However, because the amastigote 









Page 5 of 10Martinez‑Peinado et al. Parasites Vectors          (2020) 13:299  
our assay relied on Vero cells as hosts. Notably, Vero 
cells have been described to be deficient in interferon 
response due to a mutation in the simian interferon beta 
gene [27], which makes them more susceptible to infec-
tion and thereby a good system for the discovery of active 
compounds against T. cruzi.
Results obtained from the phenotypic T. cruzi growth 
inhibition assay revealed that lycorine, hippeastrine, hae-
manthamine, narciclasine and montanine were active, 
while crinine, tazettine, sanguinine and 1-O-acetylcara-
nine were inactive against the parasite (Fig. 3). Tazettine, 
sanguinine  and 1-O-acetylcaranine have been described 
as poor antiprotozoal agents before [28, 29]. Nonetheless, 
Machocho et al. [28] described that compound 3-O-ace-
tylsanguinine had some activity  (IC50 = 2.3 μg/ml; i.e. 
7.29 μM) against trypomastigotes from the T. cruzi strain 
Tulahuen C4. Although different phenotypic anti-T. cruzi 
assays were performed in each case, the results obtained 
by these authors could suggest that the presence of an 
acetyl group might increase the anti-T. cruzi activity of 
sanguinine.
On the other hand, crinine and haemanthamine are 
crinane-type alkaloids that belong to the β-crinane and 
α-crinane subgroups, respectively [30]. Other studies 
evaluating the anti-parasitic potential of alkaloids have 
reported that the presence of a methylene-dioxi group 
seemed to favour a more potent anti-parasitic activity 
[31]. This could be the explanation for the different anti-
T. cruzi activities observed by us between these two cri-
nane-type alkaloids.
The highest anti-T. cruzi activity rates were yielded 
by lycorine  [IC50 = 0.70 (0.018) µM] and narciclassine 
 [IC50 = 0.495 (0.018) µM], which exceeded in potency 
that of the reference drug BNZ (Table 1, Additional file 1: 
Figure S3). Lycorine was the first alkaloid described from 
the plant family Amaryllidaceae and one of the most 
commonly found amongst genera in the family [32]. 
Lycorine extracted from Crinum stuhlmannii, Zhepy-
ranthes citrina and Narcissus broussonetii has previously 
been tested against T. cruzi [33–35]. However, in contrast 
to our results, it was described as inactive against the 
parasite; a feature that could be explained due to the use 
of different assays. It has been reported that major differ-
ences in the activity of compounds can be found depend-
ing on the host cell line and the biological assay used [36]. 
In this respect, previous studies relied on the use of L6 
cells as a host, whereas we have used Vero cells. Lycorine 
and 1-O-acetylcaranine belong to the lycorine group but 
structurally differ in two positions of the overall structure 
(Fig. 1). In this case, the anti-parasitic activity is increased 
with the substitution of a hydrogen and an acetoxy group 
per two hydroxyl groups.
Narciclasine yielded the most potent activity against 
T. cruzi in this study (Table 1). To the best of our knowl-
edge, this compound has not been tested against T. cruzi 
before. Likewise, there are no previous reports on the 
anti-T. cruzi activity of montanine, also shown for the 
first time in this study. Montanine and haemanthamine 
showed average  IC50 values similar to that of BNZ, 
respectively 1.99 (0.089) µM and 1.59 (0.062) µM versus 
1.56 (0.070) µM of BNZ (Table 1. Additional file 1: Figure 
S3). Osorio et al. [29] have previously described the high 
activity of haemanthamine against T. cruzi  (IC50 = 1.8 µg/
ml; i.e. 5.97 μM).
Finally, we found that hippeastrine was the active alka-
loid with a higher  IC50 value  [IC50 = 3.63 (0.24) µM]. Its 
activity was lower than that of BNZ, but still fell within 
a range five times the  IC50 of the standard drug (Table 1, 
Additional file  1: Figure S3). Hippeastrine was first iso-
lated from the Amaryllidaceae plant Lycoris radiata and 
has been reported to exhibit activity against avian influ-
























































































R o u n d
Fig. 2 Quality controls of the T. cruzi growth inhibition assay (a, b), 
toxicity assay with Vero cells (c, d) and toxicity assay with HepG2 cells 
(e, f). Z’-values for each of the rounds launched are represented on 
the left (a, c, e); dashed line marks the 0.5 threshold.  IC50 and  TC50 
values of the reference drugs BNZ and DTX are represented on the 
right (b, d, f); continuous lines indicate the average values, whereas 
the dashed lines indicate ± 3 SD limits
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promising results against ZIKA virus infection have 
recently been reported with hippeastrine hydrobromide 
[38]. This was shown to remove ZIKA virus from infected 
human neural progenitors, recover a ZIKV-induced 
microcephaly phenotype in human forebrain organoids 
and even suppress virus propagation in infected adult 
mice [38]. Antiviral [37, 38], antibacterial and antifun-
gal [39] activities have been reported for hippeastrine, 
despite this, little information is available about its anti-
parasitic activity. Cedron et al. [40] tested 21 hippeastrine 
derivatives that included functional group transforma-
tions, structural simplification and dimer formation 
against Plasmodium falciparum (strain F-32 Tanzania). 
The anti-malarial activity increased by 10-fold when 
dimers were evaluated compared to the single alkaloid 
activity, suggesting an improved binding to the related 
target or the hydrolysis of the dimer onto two mol-
ecules [40]. To our knowledge, this is the first time that 
anti-T. cruzi activity is reported for hippeastrine. Results 
reported by Cedron et  al. [40] would suggest to further 
pursue research with hippeastrine derivatives against T. 
cruzi.
Identification of alkaloid compounds with specific anti‑T. 
cruzi activity
With the aim of further selecting those alkaloids with 
specific activity against the parasite and discard those 
that were toxic to host cells, we used two secondary cell 
toxicity assays with monkey (Vero) and human (HepG2) 
cells. Since the compounds activity might vary depend-
ing on the characteristics of the cell line used, performing 
the cytotoxicity assay in two cell lines will provide a more 
robust readout. Moreover, HepG2 cells are a widespread 
cellular model used to anticipate potential liver toxic-
ity of drug metabolism [41, 42]. We determined a selec-
tivity index (SI; or  TC50 to  IC50 ratio) > 10 to consider 
whether an alkaloid was suitable for further progression, 
as described elsewhere [22].
Fig. 3 Anti‑T.cruzi phenotypic assay dose‑response curves. Graphs represent mean results and SD of at least three biological replicates
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Thereafter, all the alkaloids reported as active against 
T. cruzi were analysed through both cell toxicity assays. 
All of them were more toxic to Vero cells than to HepG2 
cells (Fig.  4). The cytotoxicity values registered against 
Vero and HepG2 cells indicated that narciclasine activ-
ity was not specific against T. cruzi, as it respectively 
showed  TC50 = 0.66 (0.082) µM against Vero cells, and 
 TC50 = 2.73 (0.67) µM against HepG2 cells, resulting in 
a SI < 10 in both cases (Table 1). In addition, montanine 
with a SI = 2.53 in relation to Vero cells was not specific to 
T. cruzi either (Table 1), even though it showed low tox-
icity to HepG2 cells  [TC50 = 46.1 (11.99) µM] (Table  1). 
Something similar occurred with lycorine, which was 
weakly active against HepG2 cells  [TC50 = 21.87 (4.16) 
µM] (Table  1). Lycorine presented a SI versus this cell 
line over ten times its registered anti-T. cruzi activity, but 
turned to be toxic to Vero cells  [TC50 = 5.21 (0.80) µM] 
with a SI < 10 and thus was discarded from further pro-
gression (Table  1). We generally observed an increase 
sensitivity of Vero cells to the alkaloids when compared 
to HepG2 cells. This may have been in part due to the 
fact that compounds were incubated for a longer time 
(four versus two days) on Vero cells than on HepG2 cells.
Haemanthamine has been reported to present a 
 TC50 = 13 µg/ml, i.e. 43.14 µM for HepG2 cells [43], 
which correlates with the  TC50 value obtained in our 
study with the same cell line  [TC50 = 42.48 (6.96) µM] 
(Table  1). However, although this compound showed a 
SI > 10 with respect to HepG2 cells, when evaluated on 
Table 1 Alkaloid average  IC50,  TC50 and SI values for Vero and 
HepG2 cells
a Vero cell toxicity assay
b HepG2 cell toxicity assay
c The only alkaloid evaluated in this study that showed specific anti‑T. cruzi 
activity
Note: The standard drug BNZ is included in the first line for comparison
Alkaloid IC50 (µM) TC50 (µM)
a SIa TC 50 (µM)
b SIb
BNZ 1.56 173.4 111.15 168.76 108.18
Lycorine 0.70 5.21 7.44 21.87 31.24
Hippeastrinec 3.63 45.99 12.67 128.10 35.29
Crinine 57.93 – –
Haemanthamine 1.59 11.52 7.25 42.48 26.72
Narciclasine 0.49 0.66 1.33 2.73 5.52
Tazettine 83.03 – –
Montanine 1.99 5.04 2.53 46.10 23.17
Sanguinine 213.40 – –
1‑O‑acetylcaranine 35.49 – –
Fig. 4 Dose‑response curves obtained from the Vero and HepG2 cell toxicity assays. Vero cells toxicity assays are represented by circles and 
straight lines while HepG2 cell toxicity assays are represented by triangles and dashed lines. Graphs represent mean results and SD of at least three 
biological replicates
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Vero cells its  TC50 to  IC50 ratio was below that threshold 
and thus its anti-parasitic activity could not be consid-
ered specific (Table 1).
In contrast to all the aforementioned results, hip-
peastrine did show low toxicity against Vero cells 
 [TC50 = 45.99 (6.32) µM] and HepG2 cells  [TC50 = 128.1 
(12.26) µM], and complied with the SI window > 10 
against both cell lines (Table  1). It was the only com-
pound that had a SI > 10 versus Vero cells (SI = 12.67; 
Table 1). Additionally, hippeastrine presented the high-
est SI against HepG2 cells (SI = 35.29), with a  TC50 
value similar to that previously reported by Weniger 
et  al. [43]  (TC50 = 40 µg/ml, i.e. 126.85 µM). There-
fore, in a subsequent anti-amastigote biological assay 
we assessed whether hippeastrine anti-T. cruzi activ-
ity was indeed specific against this replicative form of 
the parasite. We found that the observed anti-amastig-
ote activity  (IC50) was 3.31 (0.39) µM, which was again 
within 5× that of the reference drug BNZ in the same 
assay  [IC50 = 1.2 (0.22) µM] (Fig. 5). Moreover, the cor-
responding SI for hippeastrine with respect to its anti-
amastigote activity will yet be > 10 (SI = 13.89 against 
Vero cells, and 38.69 against HepG2 cells).
Cytotoxicity results together with in vivo assays 
reported by Zhou et al. [38] may predict a low toxicity 
of hippeastrine in a future evaluation of its anti-T. cruzi 
activity in animal models. However, before perform-
ing in vivo studies, additional in vitro studies should 
be pursued to better validate this alkaloid. For exam-
ple, assessing its effect on a T. cruzi CYP51 target [44], 
since this drug target has been invalidated in the clinic 
[45, 46], and identifying whether it can kill dormant 
parasite forms [47]. Moreover, it would be of interest 
to determine key in vitro pharmacokinetic (PK) param-
eters such as its solubility, permeability and clearance.
Conclusions
We identified one compound with specific anti-T. cruzi 
activity, upon the evaluation of nine alkaloids puri-
fied from extracts of different Narcissus species (fam-
ily Amaryllidaceae) [16], proving that natural products 
are an interesting source to potentially identify new 
chemical structures for Chagas disease drug discovery. 
Our findings suggest that hippeastrine [17] is a relevant 
compound to be  further studied. The analysis of its 
capacity to kill parasite dormant forms, and identifica-
tion of its main target deserve further investigation in 
the future.
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